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Introduction/Background
A melanoma vaccine comprising 6 peptides presented
by Class II MHC molecules was safe and induced CD4+
T cell responses in 81% of recipients. Circulating CD4+
T cell responses to these 6 melanoma helper peptides
(6MHP) have been associated with patient survival. We
hypothesized that these intermediate length peptides
(14-23 amino acids) may also induce antibody responses,
and that antibody responses may correlate with CD4+ T
cell responses and with clinical outcome.
Methods
The original trial enrolled 39 patients who were vacci-
nated with peptides in incomplete Freund’s adjuvant plus
GM-CSF. Sera from 24 patients have been evaluated for
antibodies to the 6MHP. Antibody titer was measured
with an indirect enzyme-linked immunosorbent assay
(ELISA) of serum taken before the first vaccine and after
4-6 vaccines (5-7 weeks after the first injection). A posi-
tive antibody response was defined as the reciprocal of
the dilution that gives a fluorescent signal ten-fold
greater than that of a control serum and is greater than
100. Analysis was performed using Kaplan-Meier curves,
Chi-square analysis, and Spearman’s rank correlation
with MedCalc software.
Results
Antibody responses to the 6MHP with titers ranging from
100 to 10,889 (median titer = 2,157) were identified in
15 patients (58%), but were not detectable in 9 (42%).
There was an association between antibody response and
T cell response in the same blood samples (Spearman’s
rho= 0.51; p = 0.0115); among patients with antibody
response, 9/15 (60%) had a T cell response in the PBMC,
but in those without antibody response, only 1/9 (11%)
had a T cell response. Survival was strongly associated
with antibody response, with median survival of 1.2 years
in those without antibody response, but median survival
not reached (greater than 5 years) for those with antibody
response (p = 0.01).
Discussion
Antibody responses to NY-ESO-1 are well-characterized,
but the occurrence and significance of antibody
responses to other melanoma antigens is not known. The
peptides in this vaccine mixture are derived from gp100,
MART-1/MelanA, tyrosinase, MAGE-A3 and other
MAGE proteins. These intermediate length peptides,
administered in incomplete Freund’s adjuvant plus GM-
CSF, induce strong antibody responses. Concern that the
antibodies might interfere with immunogenicity by bind-
ing the peptides and clearing them is not supported
because the presence of antibody is associated with CD4
+ T cell response. On the other hand, these antibody
responses appear to be clinically significant because they
are strongly associated with patient survival. It is concei-
vable that these antibodies could lead to antigen-antibody
complexes that support antigen uptake and presentation
by dendritic cells.
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